BioLab at OICR is a shared instrumentation division that provides advanced state-of-the-art equipment, tools and technical know-how to support lab research activities for OICR researchers and collaborators.

The mission of BioLab is to educate, enable and inspire OICR researchers and collaborators to achieve their research objectives and professional development goals by providing instrument access, knowledge transfer and continued education on advanced cancer technologies and innovations.

BioLab provides its educational offerings through three main intersecting activities:

  • BioLab provides access to advanced technology and leading-edge instrumentation, tools and supports training that brings new knowledge and skills.
  • To maximize the exposure to current knowledge in transdisciplinary cancer research, BioLab offers participation in the networks of science communication such as online webinars and virtual events.
  • BioLab fosters educational collaboration between researchers and technology providers by sharing knowledge, resources and expertise for faster and more effective communication and learning.

BioLab Hub

To better assist OICR researchers during the COVID-19 pandemic, BioLab has extended its educational offerings by launching the BioLab Hub initiative.

BioLab Hub posts bi-weekly selections of free webinars and virtual events (symposiums, conferences, and summits) on new technologies, instrumentation, applications and innovations related to cancer research.

Upcoming Webinars and Virtual Events

Avoiding Hurdles in Molecular Assay Development
Aug 10, 2022 | 1:00 p.m. EDT

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and quality. The need for these types of assays in infectious disease diagnostics has become apparent on a wide scale, but molecular diagnostic testing is also poised to grow in other areas such as genetic testing, prenatal testing, oncology, and pharmacogenomics in the next several years.

This webinar will demonstrate how small changes to assay components (such as enzyme selection) can overcome many of these hurdles during development and significantly impact the overall quality and accuracy of an assay. The presentation will cover specific cases related to SARS-CoV-2 detection, and highlight quality and manufacturing considerations crucial to the development of a molecular assay for any target.

Biopharma 101: Analysis of Protein Therapeutics
Aug 11, 2022 | 1:00 p.m. EDT

Proteins have long been recognized as novel molecules due to their broad range of therapeutic applications. However, with the number of new and complex protein-based modalities filling development pipelines, such as conjugate, fusion, and multi-specific antibodies, complete characterization through analytical methodologies is vital to ensure the safety and efficacy of each drug candidate. These analyses include amino acid sequence confirmation, quality attribute identification and localization, determination of product & process related impurities, structural and stability testing, and much more.

Biopharma 101 is intended to provide a thorough introduction to foundational analytical characterization workflows for protein therapeutics. From the basics of protein chemistry, to utilizing mass spectrometry to identify a protein’s primary sequence, capillary electrophoresis to determine product- and process-related impurities, and microfluidic modulation spectroscopy to measure functionally relevant structural changes in biomolecules; joining this class will upgrade your protein therapeutic expertise


Lab Automation in Pathology & Genomics: Work Smarter
Aug 16, 2022 | 10:00 a.m.

Pathology testing is helping to bring more clarity about disease and treatments to patients across the world. The insights that new techniques bring in this field are time sensitive, yet, these complex workflows often rely heavily on lab staff, repetitive manual steps, and have issues scaling.

Many industries have witnessed an acceleration in the emergence of new technologies and ways of working. This is particularly evident when it comes to the integration of automation in labs.

How to Leverage Laser Capture Microdissection Technology for Advanced Oncology Research
Aug 16, 2022 | 2:00 p.m. EDT

Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing personalized treatment for patients. Tumor heterogeneity presents a challenge in oncology research as conventional methods for studying gene expression look at the tumor, ignoring the complexities of the many cell types involved in cancer progression. Laser Capture Microdissection (LCM) with the Arcturus Cellect system allows for the isolation of specific tissues and cell types from histology cross sections as well as from live cell cultures. The flexibility of the dual-laser system offers the ability to isolate various sizes of tissue, spanning from large sections of the tumor down to single-cell capture which can then be used for genomic analysis.

A Transcriptional Atlas of the Adult Human Ovary as Revealed by Spatial Transcriptomics and Single Cell Sequencing
Aug 17, 2022 | 11:00 p.m. EDT

Join this webinar to hear how Andrea Jones from University of Michigan, is using single-cell sequencing and spatial transcriptomics to create a tissue and cell atlas of the human ovary.

Analysis of 21,198 cells uncovered four primary cell types found in the human ovary: immune cells, endothelial cells, pericytes, and stromal cells. Spatial transcriptomics with the GeoMx® Digital Spatial Profiler allowed Jones and her colleagues, for the first time, to identify gradients of gene expression across the ovarian cortex and differential signaling in the follicle’s cumulus mass related to androgen production, lipid regulation, and ECM remodeling.

Oncomine Reporter – Integrated Reporting for Solid Tumor and Myeloid Somatic Variants
Aug 24, 2022 | 11:00 a.m. EDT

Next Generation Sequencing (NGS) has evolved rapidly since the first sequencing platforms were commercially released nearly two decades ago. Advancements in NGS technology today have resulted in streamlined, near end-to-end processes requiring minimal touch points by the performing scientist. One of these touchpoints remaining is the handling and analysis of data generated by NGS. In this discussion, we will cover our clinical laboratories historic usage of reporting software, including how those have developed over the years. We will also characterize our current NGS workflow utilizing the Ion TorrentTM GenexusTM System, with focus around the benefits of the integrated data analysis workflow with OncomineTM Reporter.

Supporting Development of mRNA Therapeutics by Enabling Commercial-Scale mRNA Purification
On Demand

Decades since the discovery of messenger RNA, mRNA-based therapeutics catapulted to the forefront of public consciousness in the form of vaccines to combat the COVID-19 pandemic. The potential for the therapeutic use of mRNA seems to be endless and an ever-growing number of indications are now entering the clinical pipelines. To be ready for such rapid growth, the need for scalable purification solutions for commercial production continues to rise.

To support the development of mRNA therapeutics, a novel affinity resin to isolate and purify mRNA has been developed.

Designed for scalable purification processes, POROS™ Oligo dT(25) affinity resin binds mRNA through a simple AT base-pairing mechanism.

This webinar will discuss the advantages of affinity capture of mRNA and demonstrate how this affinity resin can help to maximize efficiency and simplify your mRNA purification process from bench to manufacturing.

High-Content Phenotypic Screening – Answering Questions You Haven’t Even Asked Yet
On Demand

High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and chemical perturbations on cells. This increasingly popular method allows scientists to obtain detailed cellular profiles, consisting of hundreds of morphological features – measures of intensity, shape, size, etc. These approaches are applied in a wide range of studies, from drug discovery to functional genomics screening. Many scientists, however, do not have access to the tools or knowledge required to analyze these rich multiparametric datasets, resulting in many HC datasets being under-utilized, or even avoided.

This webinar will introduce viewers to the general concept of HC approaches, illustrated using a Cell Painting experiment. Moreover, we will demonstrate a robust and reproducible data analytics workflow to transform these rich and complex datasets into biological insight

Virtual Cancer and Immunology Research Summit 2022: Video Collection
On Demand

The SelectScience® Virtual Cancer and Immunology Research Summit 2022 featured world-class speakers and displayed the latest tools and techniques in the field. Highlights include presentations on CRISPR gene editing and modulation in drug discovery, the integration of multi-omics data for cancer research, multi-omics for early cancer detection and treatment, and the role of SCF in chromosomal instability.

Plus, listen to insightful talks about T cell targets in immunotherapy, a biologics discovery service for cell therapy, the utility of autoantibody profiling in oncology, and software for advanced statistical analysis and visualization of omics data.

Lab of the Future
On Demand

The lab of the future will not be bounded by walls, according to the global head of operations at a major pharmaceutical company. Connectedness, automation, and digitalization are already beginning to transform the biopharma laboratory

To Spatial Biology Infinity and Beyond: Discovering Novel Multi-Omic Possibilities
On Demand

Proteomic spatial biology solutions at single-cell resolution have provided an unprecedented understanding of disease biology and have become a prominent fixture across discovery, translational, and clinical research. Moreover, transcriptomic analyses have allowed scientists to analyze whole transcriptomes with RNA-seq, and single-cell RNA sequencing making it possible to profile gene expression in individual cells. The insights gathered from spatial proteomics and transcriptomics have individually provided massive contributions to tissue biology over several decades. A spatial multi-omic approach, which integrates single-cell spatial proteomic data with single-cell spatial transcriptomics, creates an exponentially larger set of possibilities.

In this GEN webinar, our distinguished guests, Dr. Niro Ramachandran and Dr. Julia Kennedy-Darling will discuss how an innovative multi omic solution can redefine how we think about spatial phenotyping and the infinite possibilities these techniques provide for spatial biology research.

Navigate the Technology Landscape in Predictive Genomics: An Introduction to Key Technology Concepts and Strategies
On Demand

Predictive genomics is a powerful capability to help predict disease risk and understand drug response in order to improve health outcomes and manage costs. This presentation will provide an overview of genome-wide sequencing and genotyping strategies for predictive genomics research. We will introduce three key whole-genome technologies: whole genome sequencing (WGS), low-pass sequencing (LPS) and genome-wide AxiomTM microarrays, and discuss how they can be integrated into technology strategies across various applications of predictive genomics research.

Dualplex Immunoassays Speed the Development of Advanced Biotherapeutics
On Demand

Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control of protein interactions. Characterizing the binding properties of complex biomolecules, such as bispecific antibodies or re-engineered probiotics, is a critical step.

In this GEN webinar, speakers will address these challenges, as they have developed and implemented a new dual-target and payload protein binding assay using AlphaPlex® technology, respectively.

You will learn the latest technology to engineer bispecific antibody therapeutics against dual targets based on the molecular interactions known to contribute to the overall disease state, as well as accurately dissect the affinities of both target binding domains directly and simultaneously in a matrixed cellular environment.

Living in a Spatial World: Characterizing the Immune Environment in Tumors
On Demand

Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors.  Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Increasing evidence suggests that the measurement of robust biomarkers through spatial analysis of the tissue will be vital to enabling rational patient selection for an improved clinical trial process and design.

Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. However, the quantitative assessment of the accuracy and precision of such multiplex panels is key for their widespread use in clinical samples.

OICR Events